Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Texas Tech University Health Sciences Center
Modality
UNKNOWN
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01442779CT.gov Clinical Trial of Low Dose Oral Interferon Alpha in Idiopathic Pulmonary Fibrosis | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Interstitial Lung Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Alpha-Interferon (this asset) | Texas Tech University Health Sciences Center | P2 | B · 57 |
| Prednisone | National Institute for Tuberculosis and Lung Diseases, Poland | P4 | BB |
| Uniprost | United Therapeutics | P3 | BB |
| Cyclophosphamide | Intergroupe Francophone de Cancerologie Thoracique | P2/3 | B |
| Sildenafil | University of California, Los Angeles | P4 | B |
| Rituximab | Royal Brompton & Harefield NHS Foundation Trust | P2/3 | B |
| Bardoxolone Methyl Ester | Biogen | P2 | B |
| Bosentan | Royal Brompton & Harefield NHS Foundation Trust | P4 | B |
| Bio 300 | Memorial Sloan Kettering Cancer Center | P2 | CCC |
+26 more in the Interstitial Lung Disease cohort
Other indications for Alpha-Interferon
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Cutaneous Melanoma | — | P3 | BBB · 74 |
| Kidney Cancer | — | P3 | BBB · 72 |
| Plasma Cell Myeloma | — | P3 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Alpha-Interferon in Interstitial Lung Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/alpha-interferon-interstitial-lung-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →